Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q3 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.21) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.18) EPS.

Several other research analysts have also weighed in on the company. StockNews.com raised Atossa Therapeutics from a sell rating to a hold rating in a research report on Tuesday, May 14th. Cantor Fitzgerald reiterated an overweight rating on shares of Atossa Therapeutics in a report on Thursday, June 20th. Finally, Ascendiant Capital Markets boosted their price target on Atossa Therapeutics from $6.00 to $6.25 and gave the company a buy rating in a research note on Thursday, June 6th.

Atossa Therapeutics Price Performance

Shares of ATOS opened at $1.28 on Monday. The business has a 50-day moving average of $1.24 and a 200-day moving average of $1.33. The company has a market capitalization of $160.97 million, a price-to-earnings ratio of -5.33 and a beta of 1.21. Atossa Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, sell-side analysts anticipate that Atossa Therapeutics will post -0.23 EPS for the current year.

Institutional Trading of Atossa Therapeutics

Several large investors have recently made changes to their positions in ATOS. PFG Investments LLC bought a new stake in Atossa Therapeutics in the 1st quarter valued at about $43,000. XTX Topco Ltd acquired a new stake in Atossa Therapeutics in the second quarter valued at approximately $29,000. Cetera Advisors LLC acquired a new stake in Atossa Therapeutics in the first quarter valued at approximately $72,000. Vanguard Group Inc. raised its position in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after purchasing an additional 78,269 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Atossa Therapeutics during the first quarter worth approximately $151,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.